Abstract: The objective of this paper was to present 12 examples of the challenges of parenteral drug administration that hospital pharmacists and other clinicians face. These examples were presented as part of a talk during the International Symposium on Infusion Technologies in November 2016. Issues included the safety and compatibility of syringes, filtration, smart pumps, beyond-use dates, closed-system transfer devices, risk measurement, traceability and labeling.
The hospital drug-use process is complex and the administration of drugs to patients presents many challenges and opportunities [1] . In the context of an International Symposium on Infusion Technologies held in Lille in November 2016, I had the privilege of opening the conference by discussing 12 examples of the challenges and opportunities that hospital pharmacists and other clinicians face in their day-to-day practices.
Drugs can be administered through a variety of enteral (e. g., oral, rectal, sublingual, nasal, transmucosal, intravaginal) and parenteral routes [2] . While subcutaneous, intramuscular and intravenous (IV) routes are the most popular parenteral ones, drugs can also be administered through intrathecal, epidural, intradermal, intraosseous, intraperitoneal, intraocular, intravitreal, intraarticular, intralesional, intracardiac, and intraarterial routes, etc. Such a wide selection of routes illustrates the large number of avenues that can be used to administer drugs to patients.
There are limited national data published on organization and practices related to drug compounding and drug administration in hospitals. In the USA, Pedersen et al. publish every year a 3-year cycle of surveys of a stratified selection of hospitals across the country. In their "dispensing and administration -2014" paper, they discussed automation and technology used to support IV drug preparation, predominant methods of compounding nutrition support preparations, the use of closed-system transfer devices and preparation activities partially or completely outsourced to a third party [3] . A similar survey of all Canadian hospitals with at least 50 acute care beds is conducted every second year by an editorial board. In 2013/14, 90 % of respondents reported they had a parenteral admixture service. Of these, 66 % of the respondents reported the provision of parenteral admixture services to ≥ 90 % of inpatients. For facilities serving < 90 %, the average percentage of inpatients receiving a parenteral admixture service reported was 23 %. Seventy-five (75) percent of respondents reported the use of IV smart pumps to administer drugs, 24 % of these respondents reported using a wireless network to upload or download data to manage their pumps [4] .
To illustrate the 12 challenges and opportunities related to parenteral drug administration, I proposed 12 questions based on current issues, research work conducted by our pharmacy practice research unit and the literature. Questions are listed according to the order used during the talk and the order does not imply any hierarchy. Table 1 shows the profile of these questions on parenteral drug administration with a brief comment on the challenges and opportunities.
Discussion
In Canada, most hospital pharmacists spend their time at the bedside, providing comprehensive pharmaceutical care to patients according to standards of practice. At the same time, some pharmacists continue to ensure a safe drug-use process at the pharmacy level, contributing to order validation, compounding supervision and dispensing.
Parenteral drug administration is associated with numerous questions, challenges and opportunities and 
Questions/issues
Challenges and opportunities
Are syringes safe as measuring devices for drugs? -Challenges -Printed visible graduation lines are equally distributed on a given syringe (e. g., a visible line is printed every . mL on a  mL syringe); a  to  % measurement error risk is usually accepted in most clinical contexts; using printed lines to measure very small doses on a given syringe can be associated with a much larger measurement error risk (e. g., measuring a . mL dose in a  mL syringe can lead to a  % measurement error, considering that a range of . to . mL can be measured, . mL being  % of the hypothetical . mL dose).
-Opportunities -Some graduations should not be printed on syringes when they are associated with a >  % measurement error risk.
Are syringes compatible with drugs? -Challenges -In , the FDA published a Drug Safety Alert regarding an interaction with rubber stoppers in certain lots of BD syringes that could cause some drugs (e. g., fentanyl, rocuronium, neostigmine, midazolam, methadone, atropine, morphine, hydromorphone, hydromorphone, cisatracurium, remifentanil) stored in these syringes to lose potency if filled and not used immediately; in Canada, syringes are medical devices and there is no single process to evaluate and review the use of these devices in a given hospital; syringes are class I devices and manufacturers are not obligated to notify customers when they modify certain components of their product (e. g., using a new type of rubber for stoppers) [].
-Opportunities -Data related to drug compatibility with drug administration devices are heterogeneous and they are fixed in time as they are published in different databases and articles; any changes in device fabrication/production are not taken into account in published compatibility data produced independently by researchers and clinicians; pharmacists should pay more attention to medical devices used for drug administration and device manufacturers should keep hospital pharmacists informed of any changes in their production of medical devices.
Should ampules be filtered by nurses and pharmacy technicians before patient administration?
-Challenges -Parenteral drugs are supplied in bags, syringes, vials and ampules; hospitals tend to minimize if not eliminate needles in the drug compounding circuit in order to better protect clinicians from accidental skin puncture; ampules are glass containers that create particulates when they are opened to withdraw the drug; some authorities (e. g., United States Pharmacopeia) recommend the use of a -micron filtering needle to withdraw most drugs from ampules to minimize particulates []; despite these recommendations, the use of filtering needles appears to be limited to the centralized IV admixture pharmacy service and not so much to patient care areas where extemporaneous preparation is done by nurses [].
-Opportunities -While there is extensive evidence about the presence of particulates associated with the use of ampules, there is limited evidence about the risks associated with these particulates in humans; further research should be conducted to confirm the risks for humans and the use of filtering needles should be standardized in hospitals.
Are smart pumps really smart? -Challenges -Smart pumps replaced "ordinary" pumps in the late s in response to numerous efforts to minimize medication errors; the notion of smartness is related to the use of a drug library that sets both soft and hard limits to inform clinicians about potential risky infusion doses and rates; while these libraries can be useful for continuous infusions, they are of limited utility or often bypassed when it comes to administering intermittent drug doses (e. g., most parenteral doses administered in a hospital are intermittent); moreover, there is limited evidence about the net impact of smart pumps on serious medication errors [].
(continued ) Are pumps well designed for healthcare workers? -Challenges -smart pumps have been developed to minimize the risks of medication errors throughout the drug-use process; as they are developed by different manufacturers, they are designed and marketed differently to gain a significant market share; numerous smart pumps encountered different safety/ design problems when they were commercialized and the FDA launched an infusion pump improvement initiative in response to the inadequate user interface design of most pumps [].
-Opportunities -The design of smart pump user-interfaces should be standardized to facilitate healthcare worker training and the use of the devices.
Are pumps well designed to treat children? -Challenges -Smart pumps are mainly used for adult patients but when used for children there is a high risk of error; both the programming and display of smart pumps should ensure a continuous monitoring of selected weight use; in pediatrics, a dosage weight has to be used to avoid continuous dose changes based on marginal weight gain due to input/output variations [].
-Opportunities -The design of smart pump user-interfaces should be standardized to display key parameters, like weight, to facilitate healthcare worker training and programming error detection.
Can a pump really be hacked? -Challenges -Smart pumps are Internet devices and can be hacked like many other healthcare devices (e. g., pacemakers, insulin pumps, security consoles)
[].
-Opportunities -Each pharmacy department should have a pharmacist/ pharmacy technician involved in technology including connectivity issues to ensure the optimal use of any device connected with the drug-use process in collaboration with information technology staff.
How should smart pump drug libraries be managed? -Challenges -Smart pumps include drug libraries that support soft and hard limits to avoid medication errors; such libraries are usually in a proprietary format and need to be developed and updated locally by pharmacists and other clinicians to meet current practice needs [].
-Opportunities -There should be a national initiative that standardizes both the format and content of drug libraries to optimize local validation and the uploading of these parameters by all hospitals.
What beyond-use date should we use? -Challenges -Drugs can be altered, both chemically/physically or microbiologically during manipulations and compounding; regulatory authorities and scientific associations propose different beyond-use dates according different compounding conditions to minimize contamination risks.
-Opportunities -The periodical surveillance of local contamination rates of centralized or decentralized compounding practices should be conducted to take into account current local contamination rates; considering the very high cost of new emerging parental drugs (e. g., monoclonal antibodies), a cost-effective approach should be put in place to establish appropriate beyond-use-dates considering scarce healthcare resources.
Are closed-system transfer devices really cost-effective? -Challenges -There are documented traces of hazardous drugs in most points of surveillance sampled in the literature; different strategies can be used to minimize these traces and reduce exposure of healthcare professionals to hazardous drugs (e. g., using appropriate personal protective equipment, training, optimal techniques at every step of the drug-use process); closedsystem transfer devices can contribute to minimizing traces of hazardous drugs but there is limited evidence about their cost-effectiveness ratio [, ].
(continued ) this paper provides a list of 12 of them. These questions/ issues highlight the need for a pharmacy department to ensure the development and maintenance of expertise in drug administration. While these 12 challenges are important, they do not exclude other important issues such as drug-drug compatibilities, drug-device interactions, drug physico-chemical stability, drug microbiological stability. Clinical pharmacists can certainly contribute to optimal drug administration in many ways. By providing decentralized pharmaceutical care in most inpatient care programs in Canada, pharmacists are well located to develop practical tools for physicians, nurses and other healthcare staff, resolve practical drug-related problems (e. g., compatibilities, line optimization, dose/interval adjustment). They can also periodically review drug libraries used in smart pumps, report recurrent drug administration-related problems to the management team and also report issues to risk management and/or pharmacovigilance and management teams for a more systematic approach and better follow-up with external stakeholders, including drug group purchasing organizations, drug manufacturers and regulatory authorities.
However, this is not enough. Further expertise should be maintained at the pharmacy level, for compounding operations as well as drug device supervision. As suggested by Accreditation Canada's required organizational practices, a multidisciplinary team should support a "documented and coordinated approach for infusion pump safety that 
Challenges and opportunities -Opportunities -The cost-effectiveness of devices added to the drug-use process should be carefully studied, as they complicate the process and introduce opportunities for error or a false sense of safety or security.
How can risk associated with drug administration be measured?
-Challenges -There are numerous incidents and accidents associated with parenteral drug administration; for instance, errors can occur at prescription, selection, validation, compounding or administration steps; various approaches are proposed to circumscribe these risks (e. g., synchronous or asynchronous direct observation, retrospective audits, accident reporting audits) [] .
-Opportunities -A failure mode effect analysis is a validated approach that can be used by clinicians to evaluate failure modes associated with parenteral drug administration, as well as the observed or perceived frequencies of these modes and the ability of clinicians to detect any failures; this analysis helps to create a comprehensive profile and determine all the risks associated with a given practice.
How far should we trace all steps related to drug compounding and drug administration?
-Challenges -While there are growing expectations that every step of the druguse process should be traced, this is more common at the pharmacy level than it is at the nursing level; barcodes, automation and software can contribute to better traceability [] .
-Opportunities -The use of an electronic medication administration record (MAR) should support the traceability of every single act performed by nurses throughout the compounding and administering drug process at the bedside; such traceability can enforce better conformity and patient safety.
Should we expect similar labeling when a drug is compounded outside the pharmacy?
-Challenges -There are many ways to label compounded parenteral doses in hospitals, taking into account, for instance, local procedures, paperwork and tools, current software and healthcare professional workloads; a significant proportion of parenteral doses are not fully labelled including all expected parameters required for safety and traceability (e. g., drug name, concentration, dilution, dose, frequency, rate of administration); national regulatory authorities and patient safety agencies require or suggest recommendations for safe labeling of parenteral doses [].
-Opportunities -There should be a national consensus on labeling parenteral commercial and compounded drugs in the pharmacy and at the bedside to ensure patient safety at every step of the drug-use process; strength per total volume followed in close proximity by strength per mL enclosed in parenthesis should be promoted.
includes training, skill assessment and a process to report problems with infusion pumps." Have you identified these experts in your pharmacy department?
